New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
07:06 EDTENDP, BDSIEndo, BioDelivery Sciences announces positive results from buprenorphine trial
Endo Pharmaceuticals, a subsidiary of Endo International (ENDP) and BioDelivery Sciences (BDSI) announced positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. The trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic pain relief compared to placebo. Additional secondary endpoints were supportive of the efficacy of BEMA buprenorphine compared to placebo. The most commonly reported adverse events in patients treated with buprenorphine compared to placebo were nausea and vomiting.
News For ENDP;BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
08:04 EDTBDSIBioDelivery Sciences to develop opioid dependence injection with Evonik
Subscribe for More Information
October 23, 2014
10:01 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:55 EDTENDPEndo initiated with a Buy at Guggenheim
Subscribe for More Information
October 21, 2014
06:37 EDTENDPEndo pullback brings buying opportunity, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use